Hemab Therapeutics Holdings, Inc.(COAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

COAG Hemab Therapeutics Holdings, Inc.

Market Closed 05-22 16:00:00 EDT

25.89

-0.41

-1.56%

盘后26.29

+0.40+1.54%

18:37 EDT

High27.04	Low25.21	Vol135.31K
Open26.30	D1 Closing26.30	Amplitude6.98%
Mkt Cap1.14B	Tradable Cap433.66M	Total Shares44.19M
T/O3.51M	T/O Rate0.81%	Tradable Shares16.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":25.89,"timestamp":1779480000000,"preClose":26.3,"halted":0,"volume":135306,"hourTrading":{"tag":"盘后","latestPrice":26.29,"preClose":25.89,"latestTime":"18:37 EDT","volume":1410,"amount":38261.974,"timestamp":1779489424326,"change":0.4,"changeRate":0.01545,"amplitude":0.0618},"delay":0,"changeRate":-0.015589353612167305,"floatShares":16750000,"shares":44192900,"eps":-1.446,"marketStatus":"Market Closed","change":-0.41,"latestTime":"05-22 16:00:00 EDT","open":26.3,"high":27.04,"low":25.205,"amount":3509381.65878,"amplitude":0.069772,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.446,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":26.3,"preHourTrading":{"tag":"盘前","latestPrice":27.02,"preClose":26.3,"latestTime":"09:23 EDT","volume":51,"amount":1385.590032,"timestamp":1779456233728,"change":0.72,"changeRate":0.027376,"amplitude":0.038403},"postHourTrading":{"tag":"盘后","latestPrice":26.29,"preClose":25.89,"latestTime":"18:37 EDT","volume":1410,"amount":38261.974,"timestamp":1779489424326,"change":0.4,"changeRate":0.01545,"amplitude":0.0618},"volumeRatio":0.893127},"requestUrl":"/m/hq/s/COAG/tweets","defaultTab":"tweets","newsList":[{"id":"2637361026","title":"Major Investor Quietly Ups Bet on Hemab Therapeutics in Fresh Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361026","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637361026?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:12","pubTimestamp":1779415969,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on May 21, 2026. Significant shareholder RA Capital Managemen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ups-bet-on-hemab-therapeutics-in-fresh-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ups-bet-on-hemab-therapeutics-in-fresh-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","COAG","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637354974","title":"RA Capital Management buys Hemab Therapeutics shares worth $120,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2637354974","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637354974?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:21","pubTimestamp":1779394860,"startTime":"0","endTime":"0","summary":"RA Capital Management, a 10% owner of Hemab Therapeutics Holdings, reported open-market purchases of 4,798 common shares at weighted average prices of $24.97 and $24.94.The RA Capital Healthcare Fund holding rose to 6,376,968 shares.Separate RA Capital-controlled positions disclosed alongside the filing included 1,009,052 shares held by Nexus Fund II, 354,938 shares held by Nexus Fund IV.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7mtZx2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management buys Hemab Therapeutics shares worth $120,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637427380","title":"Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637427380","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637427380?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:08","pubTimestamp":1779361724,"startTime":"0","endTime":"0","summary":"Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637385380","title":"Hemab Q1 FY26 net loss widens to $22.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637385380","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637385380?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:01","pubTimestamp":1779361295,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics posted a first-quarter net loss of $22.7 million, widening from $15.3 million a year earlier.Research and development costs climbed to $19.5 million from $14.1 million, while general and administrative expense rose to $4.2 million from $2.5 million.Cash, cash equivalents and marketable securities totaled $163.5 million at March 31, down from $185.5 million at the end of 2025; net cash used in operating activities increased to $21.6 million from $13 million.An upsized May IPO raised gross proceeds of $346.7 million at $18 a share, with net proceeds of about $317.2 million; the company sees its cash resources funding operations into 2029.Sutacimig won FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, with a Phase 3 pivotal trial expected to start in the second half of 2026; Phase 2 data for Factor VII deficiency and Phase 1/2 data for HMB-002 in von Willebrand disease are expected in late 2026 or early 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLRS0FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","COAG","SG9999014039.USD","NDAQ","LU2210149790.SGD","BK4588","BK4139","SG9999014013.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380100","title":"Hemab Therapeutics Holdings Inc - Q1 Net Loss $22.7 Mln, or $23.98 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380100?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAPLWH0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638701","title":"Press Release: Hemab Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637638701?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:00","pubTimestamp":1779361200,"startTime":"0","endTime":"0","summary":"Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq. Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 21, 2026  -- Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the first quarter ended March 31, 2026 and noted recent business highlights.\"As a public company we continue our journey to accelerate progress and broaden impact for people living with serious coagulation disorders with strong momentum across our clinical programs,\" said Benny Srensen, Chief Executive Officer of Hemab Therapeutics. \"The Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia recognizes both the potential for sutacimig to address a significant unmet need, and the urgency of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","COAG","BK4119","BK4139","BK4007","EMA","BK4585","BK4588","LENZ","BK4539","GT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635972775","title":"Major Investor Quietly Ramps Up Stake in Hemab Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2635972775","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635972775?lang=en_us&edition=fundamental","pubTime":"2026-05-15 10:11","pubTimestamp":1778811112,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on May 14, 2026. Significant shareholder RA Capital Managemen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-ramps-up-stake-in-hemab-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","COAG","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635172183","title":"RA Capital Management reports Hemab Therapeutics common share purchase worth $159,036.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2635172183","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635172183?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:21","pubTimestamp":1778793711,"startTime":"0","endTime":"0","summary":"RA Capital Management reported a purchase of 6,387 Hemab Therapeutics Holdings common shares at a weighted average price of $24.9.RA Capital Healthcare Fund held 6,372,170 shares following transaction.Nexus Fund II held 1,009,052 shares; Nexus Fund IV held 354,938 shares.Peter Kolchinsky, Manager, signed filing on behalf of reporting group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL2hcdzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management reports Hemab Therapeutics common share purchase worth $159,036.30","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723658","title":"Hemab Therapeutics files initial beneficial ownership statement for AI DEN-MAB LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723658?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:06","pubTimestamp":1778789171,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics filed Form 3 initial beneficial ownership statement covering 4,876,344 shares of Common Stock held directly by AI DEN-MAB LLC.Filing listed AI DEN-MAB LLC as 10% owner, with AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management LLC, and Len Blavatnik also reported as 10% owners through indirect beneficial ownership.Date of event triggering filing was 05/04/2026; filing was signed 05/14/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is sol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL3HFx09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634577572","title":"Major Investor Quietly Makes a Power Move on Hemab Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2634577572","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634577572?lang=en_us&edition=fundamental","pubTime":"2026-05-12 10:09","pubTimestamp":1778551769,"startTime":"0","endTime":"0","summary":"New insider activity at Hemab Therapeutics Holdings, Inc. ( ($COAG) ) has taken place on May 11, 2026. Ra Capital Management, LLC, a significant sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-makes-a-power-move-on-hemab-therapeutics-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-makes-a-power-move-on-hemab-therapeutics-stock-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4084","BK4139","BK4234","BK4007","BK4539","COAG","LENZ","PW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253731","title":"RA Capital Management acquires Hemab Therapeutics common shares worth $1,263,246.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253731","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253731?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:44","pubTimestamp":1778535887,"startTime":"0","endTime":"0","summary":"RA Capital Management, a 10% owner of Hemab Therapeutics Holdings, reported open-market purchases of 51,258 common shares at weighted-average prices ranging from $24.34 to $25.RA Capital Healthcare Fund’s stake was reported at 6,365,783 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL4YrqnR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management acquires Hemab Therapeutics common shares worth $1,263,246.58","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258329","title":"AI Den-Mab Llc Reports 10.4% Stake in Hemab Therapeutics Holdings Inc as of May 4 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258329?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:54","pubTimestamp":1778532867,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O0ZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232657","title":"Hemab Therapeutics director Laura Tadvalkar resigns from board","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232657","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232657?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:03","pubTimestamp":1778529837,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Holdings Inc. disclosed resignation of Laura Tadvalkar, Ph.D., from board of directors, effective immediately.Departure was not tied to any disagreement over company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL5zx4Lw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633665166","title":"RA Capital Management acquires Hemab Therapeutics common shares worth $48.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633665166","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633665166?lang=en_us&edition=fundamental","pubTime":"2026-05-07 07:17","pubTimestamp":1778109448,"startTime":"0","endTime":"0","summary":"RA Capital Management reported a sharp increase in its Hemab Therapeutics stake, lifting beneficial ownership to 6,314,525 shares held indirectly.Purchases included 2,541,250 shares at USD 18, with additional open-market buys at prices around USD 23.77 to USD 25.Holdings also reflected conversion of preferred stock into 4,838,086 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL32sYQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management acquires Hemab Therapeutics common shares worth $48.7 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633538966","title":"Hemab Therapeutics amends bylaws, ends stockholder action by written consent","url":"https://stock-news.laohu8.com/highlight/detail?id=2633538966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633538966?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:19","pubTimestamp":1777925964,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Holdings filed amended and restated bylaws effective May 4, 2026, in connection with its IPO.Stockholders can no longer act by written consent in lieu of a meeting.New bylaw framework sets advance-notice procedures for stockholder proposals, director nominations.Bylaws aligned with governance changes in restated charter, including classified board structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL9Hgswt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963921","title":"Hemab Therapeutics IPO prices at $18, raises USD 346.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963921","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963921?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924884,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics closed an upsized IPO of 19,262,500 shares of common stock at USD 18 per share.Offering included 2,512,500 shares from full exercise of underwriters’ option; all shares sold by Hemab.Gross proceeds totaled about USD 346.7 million before underwriting discounts, commissions, and offering expenses.Common stock began trading May 1, 2026 on Nasdaq Global Select Market under ticker COAG.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbCkP37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","COAG","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","BK4588","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4112","IE00B64PRP62.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633896630","title":"Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633896630","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633896630?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May  04, 2026 (GLOBE NEWSWIRE) --  Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287110/0/en/Hemab-Therapeutics-Announces-Closing-of-Upsized-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG","BK4139","BK4539","LENZ","IPOS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146146332","title":"Stock Track | Hemab Therapeutics Soars 50% on First Trading Day After IPO Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=1146146332","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146146332?lang=en_us&edition=fundamental","pubTime":"2026-05-02 01:07","pubTimestamp":1777655220,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics Holdings Inc (COAG) saw its stock price soar 50.00% intraday on Friday, marking a dramatic debut on the public market.The surge follows the company's announcement that it priced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632900306","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2632900306","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632900306?lang=en_us&edition=fundamental","pubTime":"2026-05-01 16:00","pubTimestamp":1777622402,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nAQN2LXA3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632747660","title":"BRIEF-Hemab Therapeutics Prices Upsized IPO Of 16,750,000 Shares At $18.00 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632747660","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632747660?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:57","pubTimestamp":1777589850,"startTime":"0","endTime":"0","summary":"BRIEF-Hemab Therapeutics Prices Upsized IPO Of 16,750,000 Shares At $18.00 Per ShareApril 30 (Reuters) - Hemab Therapeutics Holdings Inc COAG.O:HEMAB THERAPEUTICS ANNOUNCES PRICING OF UPSIZED INITIAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUATBV24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":-0.0777},{"period":"1month","weight":0.4383},{"period":"ytd","weight":0.4383}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hemab Therapeutics Holdings, Inc.(COAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Hemab Therapeutics Holdings, Inc.(COAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Hemab Therapeutics Holdings, Inc.,COAG,Hemab Therapeutics Holdings, Inc.股票,Hemab Therapeutics Holdings, Inc.股票老虎,Hemab Therapeutics Holdings, Inc.股票老虎国际,Hemab Therapeutics Holdings, Inc.行情,Hemab Therapeutics Holdings, Inc.股票行情,Hemab Therapeutics Holdings, Inc.股价,Hemab Therapeutics Holdings, Inc.股市,Hemab Therapeutics Holdings, Inc.股票价格,Hemab Therapeutics Holdings, Inc.股票交易,Hemab Therapeutics Holdings, Inc.股票购买,Hemab Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hemab Therapeutics Holdings, Inc.(COAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Hemab Therapeutics Holdings, Inc.(COAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction